News roundup Tuesday, November 7

» Cyxone's CEO: "Strong expert support for our strategy"
» Toleranzia reports strong quarter
» Alzinova on expectations for BIO-Europe
» Stayble Therapeutics to present Phase IIb data within a month
» Dicot updates on the Phase I study and Q3

Read BioStock's weekly newsletter for v.44 here.

During October 25-26, BioStock Life Science Fall Summit at Medicon Village in Lund. See all the highlights from the event here!

Morning news

Invent Medic receives market approval for Efemia Bladder Support in Australia. Read more.

Ziccum signs an agreement for the Vaccine Evaluation project with an American company. Read more.

Today the subscription period begins in Cyxones rights issue. Read more.

Spago Nanomedical publishes a prospectus in connection with an upcoming rights issue. Read more.

BioArctic publishes sales data for leqembi for Q3 2023. Read moreThe company also provides an update regarding Leqembi from the partner. Eisais investor presentation in connection with their Q3 report published today. Read more.

Lifecare receives regulatory approval to start the LFC-SEN-002 study. Read more.

SensoDetect announces that revised autism study promises faster results. Read more.

Egetis Therapeutics decides on directed issues of warrants and a convertible. Read more.

Prostatype Genomics decides on a rights issue of approximately SEK 47,8 million. Read more.

The board of directors of AcouBlack decides on a rights issue of units of approximately SEK 24,8 million. Read more.

Egetis Therapeutics recruiting Desiree Luthman as Vice President Global Regulatory Affairs. Read more.

Moberg Pharma implement management changes. Read more.

sectra informs about its participation at this year's international radiology trade show in Chicago, RSNA. Read more.

Vicore Pharma will participate with a presentation at the Stifel 2023 Healthcare Conference. Read more.

Nykode Therapeutics will present at the Jefferies Healthcare Conference. Read more.

Zealand Pharma will present at the Jeffries Healthcare Conference. Read more.

Invitation to presentation

BergenBio Boule Diagnostics ProstaLund

Reports

AcouBlack Bioservo Technologies Calliditas Therapeutics Carbiotix Demant Enzymatica Moberg Pharma ProstaLund

Summons

Genetic Analysis Prostatype Genomics

Changes in capital and number of votes

LifecareNovo Nordisk 1, 2

Insider trading

Novo Nordisk 1, 2 oriola

The election committee

IRLAB Therapeutics

News since Monday lunch

Cyxone published a prospectus in connection with an upcoming rights issue. Read more.

AcuCort announced that the brand name for the company's drug Zeqmelit registered for trademark protection in Norway. Read more.

FluoGuide confirmed positive topline results from the phase lla study of FG001 in head and neck cancer. Read more.

S2Medical has signed an exclusive distribution agreement with Try Medical for the Turkish market. Read more.

NextCell Pharma informed that repeated treatment with ProTrans is immunologically safe. Read more.

Spermosis received patent approval in South Korea. Read more.

Calliditas Therapeutics presented further analyses of data from the Phase III NefIgArd trial at the American Society of Nephrology (ASN) Kidney Week 2023. Read more.

Stenocare updated current sales figures here and here.

Elos Medtech announced the final outcome of the rights issue. Read more.

Last day for trading in BTU in Acarix The rights issue of units is November 9, 2023. Read more.

This morning's price development

Winner: PharmaLundensis 16,23%, Redwood Pharma 9,4%, S2Medical 7,2%, Amniotics 7,1%, Elicera Therapeutics 7,0%

Förlorare: Prostatype Genomics -59,4%, AcouSort -22,8%, Arcede Pharma -13,0%, Hemcheck Sweden -13,0%, Miris -11,7%

Index: OMXS30 2116 -0,32%, Healthcare -0,69%

More from BioStock

» Adjutec CEO on preparing for phase I
» Invent Medic expects significantly higher order intake
» Oncoinvent receives IND approval for the main indications
» Medivir's CEO comments on updated clinical data
» Strong Q3 results for Alligator Bioscience